Peletidi Aliki, Nabhani-Gebara Shereen, Kayyali Reem
Department of Life and Health Sciences, Pharmacy Programme, School of Science and Engineering, University of Nicosia, Nicosia, Cyprus.
Department of Pharmacy, School of Life Sciences, Pharmacy and Chemistry, Kingston University, London, United Kingdom.
J Res Pharm Pract. 2019 Oct 16;8(3):112-122. doi: 10.4103/jrpp.JRPP_19_3. eCollection 2019 Jul-Sep.
In the United Kingdom (UK), cardiovascular disease (CVD) is the second main cause of death (27.4%) and the leading cause of death in Greece, accounting for 48% incidences. Pharmacists, the most accessible health-care professionals, can have a key role in all stages of CVD prevention. This study aimed to explore the current and future role of pharmacists in CVD prevention, focusing on two European countries, the United Kingdom and Greece.
Semi-structured interviews were conducted with 40 community pharmacists; 20 in the UK and 20 in Greece. All interviews were audio-recorded, transcribed, and analyzed thematically.
Five main themes were identified: current pharmacists' role, future pharmacists' role, communication, resources and tools, and knowledge. Whereas pharmacists in the UK use a patient-centered approach, Greek pharmacists use a paternalistic approach. Nevertheless, the majority found it difficult to initiate a consultation. Both the UK and Greek pharmacists primarily focus on secondary CVD prevention, while dispensing prescribed medications, which is their main current role. Greek pharmacists recognized a potential role in primary prevention and early screening of CVD through the initiation of CVD prevention services with a weight management program being proposed. Barriers identified for a role in CVD prevention included: high workload in Greece and reimbursement issues and interprofessional relations in the UK.
Pharmacists in both countries perceive having a potential role in CVD prevention based on their accessibility and customer relations. The challenges include a closer working relationship with other clinicians, communication/consultation skills training, and developing a sustainable funding model for the service.
在英国，心血管疾病（CVD）是第二大主要死因（占27.4%），而在希腊则是首要死因，发病率达48%。药剂师是最易接触到的医疗保健专业人员，在心血管疾病预防的各个阶段都可发挥关键作用。本研究旨在探讨药剂师在心血管疾病预防方面当前及未来的作用，重点关注英国和希腊这两个欧洲国家。
对40名社区药剂师进行了半结构化访谈，其中英国20名，希腊20名。所有访谈均进行了录音、转录并进行主题分析。
确定了五个主要主题：药剂师的当前作用、未来作用、沟通、资源与工具以及知识。英国药剂师采用以患者为中心的方法，而希腊药剂师采用家长式方法。然而，大多数人发现难以发起咨询。英国和希腊的药剂师在配发处方药时主要侧重于心血管疾病的二级预防，这是他们目前的主要职责。希腊药剂师认识到通过启动心血管疾病预防服务（提议开展体重管理计划）在心血管疾病一级预防和早期筛查中可发挥潜在作用。确定的心血管疾病预防作用的障碍包括：希腊工作量大，英国存在报销问题和跨专业关系问题。
两国的药剂师基于其可及性和客户关系，认为自己在心血管疾病预防中可发挥潜在作用。挑战包括与其他临床医生建立更紧密的工作关系、沟通/咨询技能培训以及为该服务制定可持续的资金模式。
